Linked Life Data

19167685

Source:http://linkedlifedata.com/resource/pubmed/id/19167685

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2009-1-26
pubmed:databankReference
pubmed:abstractText
We investigated the efficacy and toxicity of combining granulocyte-colony stimulating factor (G-CSF) at standard doses with plerixafor, a CXCR4 inhibitor, to mobilize stem cells in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Patients with NHL and MM underwent mobilization with G-CSF (10 microg/kg/day) for up to 9 days and plerixafor (240 microg/kg/day), which started on the evening of day 4. Apheresis began on day 5 and continued daily until either >or= 5 x 10(6) CD34/kg were collected or to a maximum of 5 aphereses. Toxicities, increase in circulating CD34 cells/microL before and after the first dose of plerixafor, percentage of patients collecting >or= 5 x 10(6) CD34/kg, total CD34 cells/kg collected, engraftment, and exploratory efficacy analyses in heavily pretreated patients were examined. Six sites enrolled 49 patients (NHL, 23; MM, 26). All completed mobilization and 47 of 49 (96%) underwent transplant. Circulating CD34 cells/microL increased by 2.5-fold (1.3-6.0-fold) after the first plerixafor dose. The median CD34 cells/kg collected was 5.9 x 10(6) (1.5-22.5) in 2 (1-5) days of aphereses. Median days to neutrophil and platelet engraftment were 11 (8-16) and 14.5 (7-39) days, respectively. Adverse events primarily were mild nausea and diarrhea (n=24). Twenty-eight (57%) were identified as heavily pretreated patients. Their median fold increase in circulating CD34 cells/microL was 2.5 (1.4-5.0) after plerixafor, similar to minimally pretreated patients. Plerixafor and G-CSF increased circulating CD34 cells/microL and led to the adequate collection of stem cells for autotransplant in 96% of the patients. This combination may have particular value in heavily pretreated patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1523-6536
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
249-56
pubmed:meshHeading
pubmed-meshheading:19167685-Adult, pubmed-meshheading:19167685-Aged, pubmed-meshheading:19167685-Antigens, CD34, pubmed-meshheading:19167685-Blood Component Removal, pubmed-meshheading:19167685-Cell Count, pubmed-meshheading:19167685-Drug Therapy, Combination, pubmed-meshheading:19167685-Female, pubmed-meshheading:19167685-Graft Survival, pubmed-meshheading:19167685-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:19167685-Hematopoietic Stem Cell Mobilization, pubmed-meshheading:19167685-Hematopoietic Stem Cells, pubmed-meshheading:19167685-Heterocyclic Compounds, pubmed-meshheading:19167685-Humans, pubmed-meshheading:19167685-Lymphoma, Non-Hodgkin, pubmed-meshheading:19167685-Male, pubmed-meshheading:19167685-Middle Aged, pubmed-meshheading:19167685-Multiple Myeloma, pubmed-meshheading:19167685-Receptors, CXCR4
pubmed:year
2009
pubmed:articleTitle
Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
pubmed:affiliation
BMT Program, Loyola University Stritch School of Medicine, Maywood, Illinois, USA. pstiff@lumc.edu
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Multicenter Study